Michael D. West, Ph.D., is the founder and CEO of AgeX Therapeutics. Previously, Dr. West served as BioTime’s (NYSE MKT: BTX) CEO from 2007-2015, and was Co-CEO from 2015-2018. He has been a member of BioTime’s Board of Directors since 2002. Dr. West also serves as a Director of Asterias Biotherapeutics (NYSE MKT: AST). From 1998 to 2007, Dr. West served as CEO, President, and Chief Scientific Officer of Advanced Cell Technology, Inc. (now Ocata Therapeutics, Nasdaq: OCAT), a company engaged in developing human stem cell technology for use in regenerative medicine. Prior to that, he was founder, officer, and board member of Geron Corporation (Nasdaq: GERN).
Russell Skibsted, MBA,, is a seasoned executive with over 25 years experience in finance, acquisitions, partnering, marketing and operations with companies ranging from start-ups to a Fortune 5. He has over 14 years CFO experience for life science technology companies, with more than 10 years in public life science companies. Russell has a degree in Economics from Claremont McKenna College and an MBA from the Stanford Graduate School of Business.
Aubrey de Grey, Ph.D., is the Chief Science Officer of SENS Research Foundation, a California-based 501(c)(3) biomedical research charity that performs and funds laboratory research dedicated to combating the aging process. He received his BA in computer science and Ph.D. in biology from the University of Cambridge, UK. He is also Editor-in-Chief of Rejuvenation Research, the world’s highest-impact peer-reviewed journal focused on intervention in aging. He is a highly sought-after speaker who gives 40-50 invited talks per year at scientific conferences, universities, companies in areas ranging from pharma to life insurance, and to the public. He now dedicates 30% of his time to AgeX.
Hal Sternberg, Ph.D., is Vice President of Research. Prior to joining AgeX, Dr. Sternberg was BioTime’s Vice President of Research for over 25 years and was one of the company’s co-founders. Prior to that Dr. Sternberg held various positions at the University of California at Berkeley from 1982 to 1988, where he supervised a team of researchers studying Alzheimer’s Disease. Dr. Sternberg was instrumental in the development of the medical product Hextend, bringing it through regulatory approval as a blood plasma volume expander for the treatment of blood volume loss during routine surgery or emergency trauma surgery. Dr. Sternberg received his M.S. in chemistry in 1979 and Ph.D. in Biochemistry in 1982 from the University of Maryland.
Dana Larocca served as Vice President of Research and Development at ReCyte Therapeutics since 2013. She founded Mandala Biosciences, LLC in 2008 where she managed a team focused on developing targeted nanoparticle probes for identifying, tracking and manufacturing purified therapeutic stem cells. As Chief Executive Officer, she raised over $3M in non-dilutive funding from SBIR and CIRM grants. Dr. Larocca previously held joint positions at Advanced Cell Technology (now Astellas) and the Sanford Burnham Medical Research Institute. She is author of over 40 scientific publications and inventor of 23 patents and patent applications in the fields of immunotherapy, gene therapy, and regenerative medicine. Dr. Larocca holds a Ph.D. in Molecular and Cellular Biology from the University of Southern California and a B.S. in Biology from Ithaca College. She did her post-doctoral training at Harvard University.
Judith Segall is our Corporate Secretary. Ms. Segall has served on the Board of Directors of BioTime, Inc. from 1990 through 1994, and from 1995 to June 2016. She was a co-founder of BioTime in 1990.
Ivan Labat, Ph.D., is a veteran of research and development of genome informatics. Over the last 25 years, he has held several biotech industry leadership positions in design, development and implementation of the next-generation DNA sequencing methods and data analysis and curation. Ivan has received his M. S. in Molecular Biology and Physiology, and Ph. D. in Molecular Biology from the University of Belgrade.
Alfred D. Kingsley has been general partner of Greenway Partners, L.P., a private investment firm, and President of Greenbelt Corp., a business consulting firm, since 1993. Additionally, Mr. Kingsley was Senior Vice-President of Icahn and Company and its affiliated entities for more than 25 years.
Mr. Kingsley has served as Chairman of AgeX parent company BioTime, Inc. since 2009 and Chairman of OncoCyte Corp. (NYSE MKT: OCX) since 2009. He is also a member of the Board of Directors of Asterias Biotherapeutics (NYSE MKT: AST), having served as the company’s Chairman from 2012 to 2016.
Mr. Kingsley holds a BS degree in economics from the Wharton School of the University of Pennsylvania, and a J.D. degree and LLM in taxation from New York University Law School.
Michael D. West, Ph.D. has devoted his entire career to unraveling the mystery of the biological clock: from his scientific training with a focus on the biology of cellular aging, to his founding of Geron (short for Gerontology), to helming other successful biotechnology companies with a focus on immortal “pluripotent” cellular therapies, to authoring a popular book on human aging. AgeX and its clinical programs represent the culmination of his nearly three decades of research and development into the aging process.
Dr. West has served as co-CEO of AgeX parent company, BioTime, Inc. (NYSE MKT: BTX) since 2015, and before that as CEO, starting in 2007. From 1998 to 2007, Dr. West served as CEO, President, and Chief Scientific Officer of Advanced Cell Technology, which, as Ocata Therapeutics, was acquired by Astellas Pharma of Japan in early 2016.
In 1990 Dr. West founded Geron Corp. (Nasdaq: GERN), which was probably the first regenerative medicine startup, with backing from venture capital firms from Kleiner Perkins Caufield Byers, Venrock and others. For the company’s scientific team he recruited Elizabeth Blackburn, Carol Greider and Jack Szostak, who collectively went on to win the 2009 Nobel Prize in Physiology or Medicine, and for its scientific and clinical advisory board he recruited Nobel Laureates Carol Greider and James Watson, as well as Leonard Hayflick and others. While at Geron Dr. West also created the research consortium with Drs. James Thomson and John Gearhart that led to the first isolation of human embryonic stem cells.
Dr. West has been a member of BioTime’s Board of Directors since 2002, is a Director of Asterias Biotherapeutics (NYSE MKT: AST) and was a Director of OncoCyte Corp (NYSE MKT: OCX) from 2013 to 2016.
Dr. West received a B.S. Degree from Rensselaer Polytechnic Institute in 1976, an M.S. in Biology from Andrews University in 1982, and a Ph.D. from Baylor College of Medicine in 1989 concentrating on the biology of cellular aging. He is the author of The Immortal Cell: One Scientist’s Quest to Solve the Mystery of Human Aging (DoubleDay, 2003), as well as numerous papers in peer-reviewed scientific journals.
Michael H. Mulroy currently serves as President and Chief Executive Officer of of Asterias Biotherapeutics (NYSE MKT: AST), which was a subsidiary of AgeX parent company BioTime, Inc. until its deconsolidation from BioTime in May 2016. Prior to joining Asterias in June 2017, Mr. Mulroy served as a Senior Advisor to CamberView Partners, LLC, which assists companies in connection with investor engagement and complex corporate governance issues. Mr. Mulroy served until September 2014 as Executive Vice President – Strategic Affairs and General Counsel of the Autoimmune and Rare Diseases Business Unit of Mallinckrodt plc following its acquisition of Questcor Pharmaceuticals, Inc. in August 2014.
Mr. Mulroy was appointed Executive Vice President, Strategic Affairs and General Counsel and Corporate Secretary of Questcor in February 2014, having previously served as Chief Financial Officer, General Counsel and Corporate Secretary since 2011. From 2003 to 2011, Mr. Mulroy was with the law firm of Stradling Yocca Carlson & Rauth, where he served as a partner from 2004, representing Questcor and other publicly-traded companies. From 1997 to 2003, Mr. Mulroy was an investment banker at Citigroup and Merrill Lynch.
Mr. Mulroy currently serves on the Board of Directors of Asterias Biotherapeutics, Inc. and BioTime, Inc.
Mr. Mulroy earned his J.D. degree from the University of California, Los Angeles, and his B.A. (Economics) from the University of Chicago.
John F. Mauldin is a financial writer, publisher, and New York Times bestselling-author. Mr. Mauldin appears regularly on CNBC, Yahoo Tech Ticker, and Bloomberg TV and is a regular contributor to publications including The Financial Times and The Daily Reckoning. Mr. Mauldin currently serves as the President of Millennium Wave Advisors, which he joined in 2004, and is a member of the Board of Directors of Ashford Inc. Since November 2014. Mr. Mauldin has also served as Chairman of Mauldin Economics, an investment newsletter and information publishing firm.
Mr. Mauldin previously served as a member of the Board of Directors of Galectin Therapeutics, Inc. from May 2011 to December 2017. Mr. Mauldin earned his Master of Divinity from Southwestern Baptist Theological Seminary and his B.A. from Rice University.